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ABSTRACT 
Objectives: Directly measuring disease incidence in a population is difficult and not feasible 
to do routinely. We describe the development and application of a new method of estimating 
at a population level the number of incident genital chlamydia infections, and the 
corresponding incidence rates, by age and sex using routine surveillance data.  
Methods: A Bayesian statistical approach was developed to calibrate the parameters of a 
decision-pathway tree against national data on numbers of notifications and tests conducted 
(2001-2013). Independent beta probability density functions were adopted for priors on the 
time-independent parameters; the shape parameters of these beta distributions were chosen 
to match prior estimates sourced from peer-reviewed literature or expert opinion. To best 
facilitate the calibration, multivariate Gaussian priors on (the logistic transforms of) the time-
dependent parameters were adopted, using the Matérn covariance function to favour 
changes over consecutive years and across adjacent age cohorts. The model outcomes 
were validated by comparing them with other independent empirical epidemiological 
measures i.e. prevalence and incidence as reported by other studies. Results: Model-based 
estimates suggest that the total number of people acquiring chlamydia per year in Australia 
has increased by ~120% over 12 years. Nationally, an estimated 356,000 people acquired 
chlamydia in 2013, which is 4.3 times the number of reported diagnoses. This corresponded 
to a chlamydia annual incidence estimate of 1.54% in 2013, increased from 0.81% in 2001 
(~90% increase).  
Conclusions: We developed a statistical method which uses routine surveillance 
(notifications and testing) data to produce estimates of the extent and trends in chlamydia 
incidence.  
3 
INTRODUCTION 
Chlamydia is the most frequently reported notifiable infection in Europe, North America, and 
Australia with steadily increasing trends over the last decade(1-3). These trends are 
concurrent with increases in chlamydia screening rates. Because of the asymptomatic 
nature of chlamydia infection, the number of diagnoses depends on testing patterns(4). 
Consequently, it is not known whether current response efforts are having an impact on 
community chlamydia incidence and prevalence, particularly since neither parameter can be 
easily measured. Incidence is particularly difficult to measure directly, because it requires 
repeat testing. Prospective longitudinal studies of the same individuals(5) can almost never 
be incorporated into routine national surveillance due to cost, and retrospective cohorts are 
currently not feasible as levels of repeat testing are low in the general population(6). An 
alternative approach to direct measurement is to infer prevalence and incidence by using all 
relevant and available data coupled with a quantitative framework which links these data to 
the epidemiological indicators. This epidemiological modelling approach is appealing 
because it does not require additional primary data collection, is not costly, and can produce 
estimates that can be applied repeatedly every year. Modelling approaches have been used 
to assess the potential impact of chlamydia screening programs and their cost-
effectiveness(7, 8). Modelling approaches have also been used to infer population incidence 
of other infectious diseases using routine surveillance data, for example, for HIV(9) but not 
for chlamydia.  
Like some other countries, Australia routinely monitors chlamydia by the reported numbers 
and rates of notifications of diagnosed cases(10). However, the systematic increase in 
testing rates in Australia over the last decade is believed to be largely responsible for the 
increasing number of notifications(11). Despite increases, testing rates still remain relatively 
low with only about 10% of the most affected age group, 16-29 year olds, tested each 
year(12). There are no estimates of incidence trends available in the general population in 
Australia. There are also no methods available from similar countries which estimate 
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incidence from notification and testing data. Hence, we aimed to develop a method for 
inferring chlamydia incidence in Australia using routinely collected surveillance data 
(primarily national notifications and testing), ensuring consistency with other relevant data 
sources, and to apply these estimates to assess trends over time.  
METHODS 
We estimated chlamydia incidence in the Australian population from 2001 to 2013 using a 
Bayesian statistical method based on a decision-pathway model.  
Model 
The decision-pathway of this approach is a probabilistic tree to represent the branches along 
which people in the population can end in each calendar year as either acquiring or not 
acquiring chlamydia infection, developing symptoms, being tested and treated, and being 
notified as a case. Stratified by age and sex, each individual in the population has an 
assigned probability of each step along the branch over the course of each year (Figure 1). 
For some branches, the model parameters (probabilities) are strongly constrained a priori 
from estimates in the literature, while other parameters must be informed by fitting the model 
to the surveillance data of numbers of people tested and numbers diagnosed with 
chlamydia.  
To follow the effects of an evolving disease burden and changes in public awareness of, and 
access to, relevant public health programs we allowed the annual infection and 
asymptomatic screening probabilities to vary yearly by age group and sex using a flexible, 
stepwise Gaussian process model while all other input parameters were fixed in time. 
Priors  
Following a standard Bayesian approach, we adopted independent beta distributions for 
priors on the time-independent probability parameters; the two shape variables of each beta 
distribution were chosen so that the beta prior will be closest (using the Kullback-Leibler 
divergence) to a triangular distribution for the corresponding parameter, which requires only 
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an initial estimate of the minimum, mode, and maximum for its characterisation (sourced 
directly from peer-reviewed literature or obtained from expert opinion).To best facilitate the 
calibration without sacrificing model flexibility we adopted multivariate Gaussian priors on 
(the logistic transforms of) the time-dependent parameters, using the Matérn covariance 
function(13) to favour small changes over consecutive years and across adjacent age 
cohorts (with independence between the sexes). Table S1 summarises the values chosen to 
specify the priors on the time-dependent and time-independent parameters. 
Calibration data sources 
The two main data sources used to calibrate the model were: 
 National notification data (numbers of reported diagnoses per year) published by the 
Australian National Notifiable Diseases Surveillance System (NNDSS)(10); and  
 National testing data collected by Medicare(14) (the Australian universal health 
insurance scheme that rebates tests conducted by the majority of health providers). It 
includes unique codes for a chlamydia test. However, tests conducted in public hospitals 
and most sexual health services are excluded, as these are funded separately and are 
not centrally collated. Medicare data on chlamydia tests were not available from 
November 2005 to April 2007 because the unique codes for identifying a chlamydia test 
were temporarily removed and any chlamydia tests conducted were recorded using a 
non-specific code that included tests for other genital organisms(14). Although, tests 
conducted in public hospitals and most sexual health services are excluded, 82% of all 
chlamydia tests were conducted at GP clinics(15).  
In addition, annual population census estimates published by the Australian Bureau of 
Statistics (ABS)(16) were used for sex and age group population sizes. 
Model calibration methods 
A sequential Monte Carlo (SMC) approximate Bayesian computation (SMC-ABC) 
procedure(17) was used to identify the optimal fit of parameters, infer annual incidence, and 
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gauge uncertainties when comparing the model with observed notifications and testing 
surveillance data. The model simulations were matched to: (i) the annual notification counts 
reported; and (ii) the annual test counts reported by Medicare for 2001-2005 and 2008-2013. 
The ABC algorithm allows for rigorous statistical inference from complex systems for which 
the true likelihood function may be computationally intractable but simulation from the model 
is comparatively cheap (18) (see Supplementary Material for detail).  
Model validation 
Model outcomes were compared with independent empirical epidemiological measures. 
Chlamydia prevalence amongst 16-29 year olds was measured in 2011 by the Australian 
Chlamydia Control Effectiveness Pilot (ACCEPt) – a randomised controlled trial of a 
chlamydia testing intervention in 150 general practice clinics(19). Since ACCEPt was 
conducted among sexually active 16-29 year olds, prevalence estimates from the study were 
scaled down to account for the prevalence of sexual activity in these age groups (the 
Australian study of health and relationships found that 66%, 89% and 95% of males and 
56%, 90% and 97% of females aged 15-19, 20-24 and 25-29 years, respectively, have been 
sexually active(15)). The model outcomes were also compared to a study which measured 
incidence and prevalence among a cohort of young women (see Discussion)(5). 
RESULTS 
Data trends 
The number of chlamydia notifications in Australia increased markedly over the study period, 
with 82,484 notifications in 2013 compared with 20,224 in 2001 (>300% increase). During 
the same period, the number of chlamydia tests recorded by Medicare increased by ~500% 
with 1,090,705 tests rebated in 2012 compared with 184,024 in 2001 (Figure S1). 
Model calibration  
To assess the accuracy of our calibrated model, we compared the 95% credible intervals 
(CIs) from the model output to the corresponding NNDSS and Medicare data in 15-24 and 
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>25 year old males and females. The comparison showed a close agreement between the 
model outcomes and the actual data (Figure 2a-b).  
Model validation 
Figure 2c presents a comparison between the model-based (median and 95% CI) estimates 
of chlamydia prevalence and measured prevalence among 16-24 year old males and 
females in 2011 from the ACCEPt study (scaled down to adjust for rates of sexual activity). 
The comparison shows broad agreement between the model estimates and the measured 
prevalences for younger males and older females. The ACCEPt estimate for older males is 
so uncertain that it covers almost our entire credible range for all age-sex cohorts but has a 
mean below our estimate. Of greater concern is the relatively narrow range of the ACCEPt 
estimated prevalence for young females at 3.6-5.6% (95% CI), which lies above our model-
based estimate of 3.2-3.6%; however, the quoted CI for the former excludes uncertainty in 
the estimate of the sexually active proportion in this cohort, which together with some 
additional variance contribution from the particular geographical coverage of the ACCEPt 
pilot study could reasonably account for the discrepancy here. 
Incidence estimates 
The model inferred that the estimated total number of people acquiring chlamydia per year in 
Australia has increased from 160,000 (95% CI: 157,000-164,000) in 2001 to 356,000 
(344,000-367,000) in 2013, a 120% increase. This population chlamydia incidence 
corresponds to a per-person rate of 2.0% (1.9%-2.1%) in males and 1.1% (1.1%-1.2%) in 
females in 2013 overall.  
The model outcomes suggest that chlamydia incidence has been generally increasing over 
the past decade among both sexes and across all reported age groups (Table 1, Figure 3). 
Incidence rates were greatest in people aged 15-24 years and increased historically: from 
2.7% in 2001 to 7.0% in 2013 for males and from 3.1% to 5.6% for females, but appears to 
have levelled off in the last two years (Figure 3). Among 25-34 year olds, estimated 
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incidence increased from 2.2% to 4.1% in males and 1.1% to 1.7% in females; in those aged 
35 years or older, estimated incidence increased from 0.39% to 1.0% in males and 0.1% to 
0.27% in females from 2001 to 2013.  
DISCUSSION  
This study provides a new approach to estimate trends in chlamydia incidence in the general 
population. It uses a simple model which translates routinely available surveillance data and 
a limited number of key assumptions into estimates of incidence. Since this method relies 
only on routinely available data, chlamydia incidence can now be estimated easily on an on-
going basis; non-routine data (e.g. prevalence or incidence studies) can be used for model 
calibration or reserved for validation. A recent modelling study, from the UK, used two 
separate methods to estimate incidence of chlamydia(20). The first method used existing 
incidence estimates while the other used prevalence estimates; neither of which is a routine 
data source, and hence cannot be used for routine incidence estimation. 
Our model shows large increases in incidence. We believe such increases are plausible. 
Firstly, there has been an increase in the number of notifications(10). Secondly, prevalence 
as notified by the ACCESS sentinel surveillance system at sexual health services across 
Australia(11), showed increasing trends in young people aged 15-29 between 2006 and 
2010 – which when expanded to the whole time period will be more pronounced. Thirdly, 
positivity among 15-24 year old men, as calculated by notification-to-testing ratio has 
remained roughly constant. Simple mathematics (not presented here) suggest that: a) if 
incidence increases but testing stays constant, the positivity must increase; b) if testing 
increases but incidence stays constant, positivity must decrease; and c) positivity can only 
remain constant, if both incidence and testing decrease or both increase or both remain 
unchanged. Since we know that testing rates have increased substantially and positivity 
rates are estimated to have remained steady, incidence must have increased for this age 
group. We note that other sex-age groups did not have constant positivity rates over time 
despite increased testing. Fourthly, there is a relationship between changes in testing rate, 
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prevalence and positivity rate. Figure S2 demonstrates this relationship. Here, we observe 
the ‘positivity contour’ association between prevalence and testing rates. It infers how 
prevalence has likely changed over time while maintaining a steady positivity rate and 
increasing testing rates for 15-24 year olds. This figure also relates testing and positivity 
rates to prevalence, had there been other testing or positivity data for this age group. In 
addition, there has been an increase in reported sexual risk taking behaviour in young 
people in Australia. The Australian sexual health surveys among secondary students show 
that condom use at the most recent sexual encounter decreased over the last 10 years; and 
the proportion of young people reporting 3 or more sexual partners increased over this 
period (21).  
Like all Bayesian analyses, this study relies on both the validity of the modelling assumptions 
and the suitability of the prior distributions adopted. Perhaps the greatest limitation arising 
from the former is that the model does not take into account any re-infections or re-testing. 
High repeat positive test rates have been reported for chlamydia in young women in 
Australia (22.3 per 100 person years)(5). In our analyses, all repeat positive tests were 
considered incident infections since the end point of this model’s pathway was notification of 
infection. Since a vast majority of infections are asymptomatic and undiagnosed (and hence 
only cured naturally or by background antibiotic use) the contribution of reinfections has 
been assumed to be small for this study. A study by Althaus et al reported that re-infections 
have little impact on the estimates of the average duration of infection(22).  
Another key assumption is that the designated time-independent parameters of our model 
are indeed time-independent. These can be divided into: (A) those related to disease (the 
proportions of asymptomatic infections in men and women and the probability of naturally 
clearing the infection within a year); (B) those related to testing (true positive and false 
positive test rates, in the context of the same underlying diagnostic technology since 
1999/2002 when Australia adopted nucleic acid amplification testing (NAAT)(23)); and (C) 
those related to behaviour and practices (probabilities of being tested for chlamydia, the rate 
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of background antibiotic use, and case reporting completeness). The parameters in group A 
are strongly expected to be truly time-independent given no evidence for biological changes 
in the pathogen; likewise for the parameters in group B as NAATs have been used over the 
study period. However, the time-independence of the parameters in group C is an 
assumption representing the simplest hypothesis in the absence of relevant data. Although 
there may be some minor differences, it was assumed that all these time-independent 
parameters (except for the proportions of those with symptoms) were the same for both 
sexes.  
Our model suggests that incidence increased at a faster rate in males. Although incidence 
was higher in females than males aged 15-24 years until 2005, it was higher in males after 
2005. Also, it was higher in males than females aged 25-34 and >34 years for all years. 
More chlamydia diagnoses occur amongst females, reflecting a higher rate of asymptomatic 
testing among females. However, as there is little known about the natural history of 
chlamydia infection in men, with most studies reporting on natural history conducted in 
women(24, 25), it seemed reasonable to assume that the probability of natural clearance of 
infection over a year is the same for both sexes. It is also notable that our model does not 
differentiate between heterosexual versus homosexual men nor other sexual mixing 
patterns.  
Through a careful sensitivity analysis, presented in the Supplementary Material, we have 
confirmed the robustness of our results against moderate changes to our input priors. For 
four of our nine time-independent parameters, the data are highly informative (and our 
results are largely insensitive to our prior assumptions); these are: the asymptomatic 
proportions in men and women , the probability of natural clearance over a year, and the 
false positive rate of testing. The remaining five time-independent parameters for which our 
prior assumptions dominate are: (a & b) the probabilities of attending and consequently 
testing for symptomatic infections, (c) the true positive rate of the diagnostic test, (d) the rate 
of background antibiotic use, and (e) the probability of reporting a test. Of these, all except 
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the second and third (the focus of our prior sensitivity analysis) have narrow prior ranges 
based on reliable references and thus would not be expected to substantially alter our 
overall quantitative findings.  
To date, only one prospective cohort study of chlamydia in the general population has ever 
been conducted in Australia: the chlamydia incidence and re-infection study (CIRIS)(5). This 
study included only young women aged 16-25 years and reported a chlamydia prevalence of 
4.9% (95% CI: 3.7% - 6.4%) and an incidence of 4.4 per 100 person-years (3.3 - 5.9) in 
2007-2008. The incidence reported by CIRIS is similar to the estimates produced by our 
model: 5.6% (5.2% - 6.1%) and 5.7% (5.3% - 6.3%) in 15-24 year old women in 2007 and 
2008 respectively. Multivariate analysis from CIRIS showed that younger women (16-20 
years) were more likely to have an incident infection(5), consistent with our study. CIRIS also 
reported that recent use of antibiotics was protective against incident infection(5). We 
accounted for background antibiotic use as a model parameter to allow for self-cure when 
antibiotics were taken for any reason, although the assumed level in our analyses may differ 
to actual levels of use. 
Although there is a dearth of studies reporting on chlamydia incidence in the general 
population internationally, a study from the US(26) estimated that there were about 2.86 
million incident infections in the US in 2008. The number of chlamydia notifications in 2008, 
in the US, was 1.2 million which gives an incidence-to-notification ratio of 2.4. This is less 
than the incidence-to-notification ratio of 4 for Australia based on our estimates. The 
difference in ratios between the US and Australia could reflect differences in testing patterns 
or epidemiology between these settings and/or the methods used to calculate the ratios. It 
would be valuable to compare these factors in future studies.  
Historically, Australia has based its chlamydia prevention strategies on the number of 
diagnoses notified. However, in 2013 the number of notifications among people aged 15 
years and older (n=82,484) represents only 23% of all estimated incident infections 
(n=356,000 according to this study) in the year. Thus, the estimated incidence-to-notification 
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ratio in Australia was 4.3 in 2013. This also implies that 77% of new chlamydia infections 
remain undiagnosed. Our findings also suggest that incident infections of chlamydia more 
than doubled between 2001 and 2013, from 160,000 to 356,000 infections. However, this 
relative change (120%) is substantially less than the increase (>300%) in numbers of 
chlamydia notifications reported during the same time. This clearly demonstrates that the 
increase in the scale of the infection as observed by the trends in notification numbers has 
been misleading and is somewhat an artefact of increased testing(11).  
This study has reported a new approach to estimating chlamydia incidence in the general 
population using routine testing and notification data. Other countries that collate and report 
data on chlamydia diagnoses and testing numbers can also use this method to estimate 
chlamydia incidence.  
 
KEY MESSAGES 
 The estimated total number of people acquiring chlamydia per year in Australia has 
increased by ~120% over 12 years. 
 The estimated ratio of incidence to notification in Australia was 4.3 in 2013. 
 A Bayesian statistical approach, using routine testing and notification data, can be 
employed to estimate incidence. 
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Figure 1: Pathways of chlamydia infection to be notified to the NNDSS. Each parameter 
represents the (annualised) probability of progressing over a particular step. The light grey 
branches/boxes represent drop-outs from the notification count, but those reaching the testing phase 
will (if correctly reported) nevertheless contribute to the total test count. 
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Figure 2: Model calibration and validation against chlamydia data, by age group and 
sex, 2001-2013: (a) notifications, (b) tests, (c) prevalence 
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Figure 3: Estimates of chlamydia incidence in Australia, by sex and age group, 2001-
2013: (a) Number of incident infections; (b) Incidence rate as a percentage per person 
per year. 
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Table 1: Estimates of annual chlamydia incidence, by sex and age group, 2001-2013 
Sex Males Females 
Age 15-24 years 25-34 years >34 years 15-24 years 25-34 years >34 years 
 
Incidence 95% CI Incidence 95% CI Incidence 95% CI Incidence 95% CI Incidence 95% CI Incidence 95% CI 
2001 2.7% 2.5-3.0 2.2% 1.9-2.4 0.39% 0.32-0.46 3.1% 2.8-3.4 1.1% 
0.96-
1.2 
0.11% 0.09-0.13 
2002 3.3% 3.0-3.7 2.5% 2.2-2.7 0.44% 0.38-0.50 3.6% 3.4-4.0 1.2% 1.1-1.3 0.12% 0.10-0.13 
2003 4.0% 3.7-4.4 2.9% 2.6-3.1 0.50% 0.45-0.57 4.2% 3.9-4.7 1.4% 1.3-1.5 0.13% 0.12-0.15 
2004 4.7% 4.3-520 3.3% 2.9-3.5 0.58% 0.51-0.66 4.8% 4.4-5.3 1.5% 1.4-1.7 0.15% 0.13-0.17 
2005 5.3% 4.9-6.0 3.5% 3.0-3.7 0.64% 0.57-0.74 5.2% 4.8-5.7 1.6% 1.5-1.8 0.16% 0.15-0.19 
2006 5.8% 5.3-6.6 3.6% 3.2-3.8 0.71% 0.64-0.81 5.4% 5.1-6.0 1.7% 1.5-1.8 0.18% 0.16-0.21 
2007 6.2% 5.7-7.1 3.7% 3.2-3.9 0.77% 0.69-0.89 5.5% 5.2-6.1 1.7% 1.5-1.8 0.20% 0.18-0.23 
2008 6.8% 6.3-7.6 3.8% 3.4-4.1 0.82% 0.73-0.94 5.7% 5.3-6.3 1.7% 1.5-1.8 0.22% 0.19-0.25 
2009 7.5% 7.0-8.3 4.0% 3.5-4.2 0.88% 0.78-1.0 5.9% 5.5-6.6 1.7% 1.5-1.8 0.23% 0.20-0.26 
2010 7.8% 7.3-8.8 4.1% 3.6-4.3 0.94% 0.82-1.1 6.1% 5.6-6.8 1.7% 1.5-1.8 0.24% 0.21-0.28 
2011 7.7% 7.3-8.8 4.2% 3.7-4.4 0.99% 0.89-1.1 6.0% 5.6-6.8 1.7% 1.5-1.8 0.25% 0.22-0.29 
2012 7.5%  7.1-8.5 4.2% 3.7-4.5 1.0% 0.92-1.2 5.9% 5.5-6.6 1.7% 1.6-1.9 0.26% 0.23-0.30 
2013 7.0% 7.0-6.8 4.1% 3.6-4.4 1.0% 0.91-1.2 5.6% 5.1-6.3 1.7% 1.5-1.9 0.27% 0.24-0.33 
% 
increase 
160%  86%   156%   80%   54%   170%   
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Supplementary Material 
In this Appendix we present further mathematical details of our approach for estimating 
chlamydia incidence.  
Decision pathway probabilistic model 
In this study we adopt a pragmatic approach to inferring the annual variation in the incidence 
and screening rates, in which we simulate its link to the observed routine surveillance counts 
of chlamydia diagnoses reported, and chlamydia tests conducted, through a conditional 
probability model (as represented by the decision pathway diagram shown in Figure 1 of the 
main text). According to age and sex, each individual in the population is assigned a 
particular probability of acquiring chlamydia infection, developing symptoms, being tested 
and treated, and being notified as a case, over the course of each year. For a symptomatic 
infection to be notified we suppose the individual must seek medical care (with probability 
patt.|symp.), the clinician tests the patient for chlamydia (with probability ptest|symp.), the test 
returns a true positive result (ppos.), which in turn is reported (prep.). Patients with 
asymptomatic infection, or even those who do not acquire chlamydia infection at all, may 
also be notified (erroneously, in the latter case) if they are screened for chlamydia (with 
annual probability, ptest|asymp.) and the diagnostic test returns a true positive (ppos.) or false 
positive (pfalse pos.) result, respectively.  
Untreated infections may clear naturally over the course of a year (with probability pself cure, n.), 
or as a consequence of background antibiotic use (with probability pself cure, a.); those that do 
not clear infection are carried over to the following year, introducing a non-negligible (anti-
)correlation in the notification and test counts across both calendar years and age groups 
(i.e., the more cases treated in a given year, the fewer that will carry over to the following 
year). Hence, although we allow the annual infection and asymptomatic screening 
probabilities to vary yearly we anticipate a degree of correlation, as reflected by our 
multivariate Gaussian priors on these parameters. All other input parameters, as 
summarized in Table S1, are taken to be constant in time. 
If it is assumed that all untreated infections clear within the calendar year, estimates of the 
parameters in the model can be obtained by solving equations involving the model 
parameters and also the observed routine surveillance counts. In particular, the following 
equations are obtained when equating the observed value with that predicted by the 
conditional probability model: 
Number of notifications/Total population [in a given age–sex cohort] = 
 
    . inf . . . .| . | . . .| . inf . .| . .1 1rep pos asymp att symp test symp asymp att asymp att asymp false posp p p p p p p p p p p      ; 
and 
Number of tests/Total population [in a given age–sex cohort] = 
    . inf . . .| . | . . .| . inf . .| .1 1rep asymp att symp test symp asymp att asymp att asympp p p p p p p p p      . 
Given input values for each of our time-independent model parameters and using the 
available NNDSS notification and Medicare test data to compute the left-hand side of each 
equation allows for simultaneous solution for the two unknown time-dependent parameters: 
the probability of acquiring infection per year (or incidence) and the proportion of 
asymptomatic people who are tested each year. In particular, taking the positive solution of 
the resultant quadratic equation yields: 
Probability of acquiring chlamydia per year =  
 
   
.
. . .| . | . . .| . . .
Number of notifications/Total pop.  Number of tests/Total pop.
1
false pos
rep asymp att symp test symp asymp att asymp pos false pos
p
p p p p p p p p
 
  
. 
With untreated infections allowed to progress (realistically) from year-to-year under our full 
model, this approximate solution needs adjusting; the corresponding likelihood function for 
Bayesian inference when infections are carried forward each year is not readily tractable 
(analytically or computationally). Instead we require an approximate Bayesian approach 
based on a comparison of data simulated from the model and the actual data (referred to as 
approximate Bayesian computation, or ABC).  
Simulations 
The simulation of datasets—i.e., annualized time series of notification and test counts by age 
and sex from 2001 to 2013—from our conditional probability model proceeds as follows. For 
a given set of (both time-dependent and time-independent) input parameters we draw (from 
the binomial distribution) in each year only the necessary annual totals of new symptomatic 
and asymptomatic infections in each age–sex cohort, adding these to the burden of uncured 
infections carried over (and aged) from the previous year, and we then simulate 
observations following our decision pathway diagram. With each simulation step there 
emerges a slight stochasticity from the binomial sampling process (i.e. counts of ‗successes‘ 
within a fixed sample of common ‗success‘ probability), while the ageing of uncured 
infections across cohorts yields a modest degree of year-to-year correlation. To initialize the 
model at an equilibrium prevalence level we run these simulations over a lead-in period of 
seven years (which are discarded) under our starting parameter set (for the year 2001). All 
code for running these simulations was built in the R statistical computing environment and 
is available from the authors upon request. 
Approximate Bayesian Computation via the Sequential Monte Carlo Algorithm 
Originally developed in the late 1990s to solve complex inference problems in the study of 
population genetics (e.g. [1]) the statistical basis of ABC is the replacement of direct 
likelihood evaluation in Bayes‘ theorem with a proxy based on the comparison of simulated 
and observed datasets (or, more commonly, key summary statistics thereof). In effect, the 
complete-likelihood Bayesian posterior,  
                              
 ( | )    ( | ) ( ) 
is approximated by the ABC posterior,  
                                              
    (    | )    (  | )   ( , (  )  ( )-   ) ( ) 
That is, the prior,  ( ), is weighted not directly by the likelihood,  ( | ), but indirectly by the 
proportion of simulations,   , from a given set of input parameters,  , that produce simulated 
datasets,  (  ), that are ‗close‘ enough to the observed data‘s summary statistic,  ( ). Here 
‗close‘ is defined through the distance metric,  ,   -. In our notation,    (   ) represents the 
Indicator function, which is equal to 1 if the distance between the observed and simulated 
data is below a user-chosen threshold   and 0 otherwise. Note that the above ABC posterior 
is defined as a joint distribution over   and   , so that samples from the corresponding 
marginal ABC posterior distributions for   and    are also obtained as a by-product. For an 
introductory review of ABC methods (with a focus on their application in evolutionary biology) 
the interested reader is referred to [2]; and see [3] for a pioneering application in 
epidemiology. The discrepancy distance metric adopted for our particular ABC analysis was 
the sum of the absolute fractional differences of notification and test counts in each of the 
age-sex cohorts between the model and the data; i.e., 
 , (  )  ( )-   ∑|       |     
Since there is a limited amount of stochasticity in our model, we are able to compare 
observed and simulated datasets directly without any summarisation.  
As is typical in most Bayesian problems, the ABC posterior is not available in closed form. 
Instead, an algorithm is developed in order to generate samples from the ABC posterior and 
use these samples to approximate quantities of interest. In our application, we are interested 
in the posterior mean of the incidence level over time for various sub-populations and also 
the corresponding credible intervals, which quantifies the most likely values of incidence 
based on prior information and also the information contained in the observed data. The 
simplest algorithm available to sample from the ABC posterior, is the ABC rejection 
algorithm (see [5]). Under ABC rejection one simply draws a sample of N parameter vectors, 
* + , from the prior, simulates a dataset for each, computes the corresponding vector of 
discrepancy distances, * + , and then accepts as the ABC posterior only those * + with * + 
in the lower q quantile of the * + . The choice of q ultimately reflects a trade-off between the 
‗closeness‘ of the ABC posterior to the true (i.e. complete likelihood) posterior and the Monte 
Carlo error associated with how many samples are kept in the ABC posterior. The major 
issue with the ABC rejection algorithm is that it is highly inefficient if the posterior distribution 
of interest is very different from the prior distribution. This problem is exacerbated when 
there is a large number of parameters being estimated. For our application, there is simply 
far too much computation required to reduce   down to an acceptable level. Therefore we 
seek a more computationally efficient approach. 
The sequential Monte Carlo (SMC) family of statistical learning algorithms offers a powerful 
means for generating computational approximations to complex (posterior) probability 
distributions and has been successfully applied in ABC applications. In the context of ABC, 
SMC ABC algorithms involve defining a sequence of ABC posterior distributions with a 
decreasing sequence of ABC tolerances,            (our algorithm determines this 
sequence adaptively), where    is the target ABC tolerance or the best tolerance that can be 
achieved within a reasonable computational budget. The main idea is to refine the 
distribution from which parameter values are drawn (instead of the prior) so that parameter 
values with non-negligible posterior support are drawn more often, leading to an overall 
much higher acceptance rate than is usually obtained in ABC rejection. The reader is 
referred to [23] of the main paper for full details of the SMC ABC approach we adopt.  
Despite the improved efficiency of SMC ABC, it was also necessary to be reasonably 
precise in our prior specification regarding the expectation of moderate correlations year-to-
year in the incidence rate of each age-sex cohort, and between those of nearby age-sex 
cohorts at fixed year; and likewise for the time dependent asymptomatic testing (screening) 
rate. To this end, we chose a multivariate Gaussian prior with Matérn covariance structure 
(given a correlation range of 12 years and a smoothness index of 1.5) acting on the logistic 
transformed analogues of pinf., t yearly (or ptest|asymp., t accordingly). Here the logistic transform, 
qinf., t = log(pinf., t / [1-pinf., t ]), transforms standard probabilities to random variables that have 
no upper or lower bound. The choice of the Matérn function here is not significant in of itself; 
rather its use was motivated by convenience since the Matérn guarantees a positive-definite 
covariance matrix and its properties are familiar from its routine use in geostatistical 
analysis. Interestingly, even though we then adopt broad, relatively non-informative prior 
variances in these (logistic transformed) Gaussian priors (as specified in Table S1) the 
effective reduction in the ―volume‖ of the prior predictive distribution introduced by our 
implementation of a well-motivated correlation structure in the prior (as opposed to the naïve 
default of strict independence year-to-year) was observed to yield great improvements in the 
ABC convergence rate. Using our SMC ABC method we are able to reduce the ABC 
tolerance to less than a 5% mean fractional error in the fit to each of the 224 notification and 
test counts in our observed NNDSS benchmark. 
Finally, it is important to emphasise that although at face value our application to the 
estimation of chlamydia incidence and prevalence amongst the Australian population using 
the chlamydia notification and testing data might appear highly specialised, the ABC-based 
methodology presented here should in fact be viewed as rather more general than this. With 
the defining characteristic of the ABC algorithm being to allow indirect inference of model 
parameters from complex datasets—especially where the likelihood function formally 
connecting the two is rendered intractable by complex selection effects or (as in this case) a 
third-party monitoring network—one might expect the approach to be useful in revealing the 
long-term trends of other transmissible infections. While the only direct, large-scale estimate 
of Australian chlamydia prevalence available from the ACCEPt study was here reserved for 
validation purposes, it is important to note that it could also have been used for model fitting 
simply by incorporating this data into our ABC discrepancy distance. In this sense, the power 
of ABC for enabling inference from multiple, heterogeneous datasets remains to be properly 
explored in the epidemiological context (though see [45] for a first step in this direction) and 
should be recommended as an important direction for future research. 
Prior-Sensitivity Analysis 
As in all Bayesian analyses it is important to bear in mind the possible sensitivity of the 
target posterior estimates to the assumed priors. Of principal concern for the present study is 
that although the inferred trends in our time-dependent parameters, pinf., t and ptest|asymp., t, are 
overwhelmingly data-driven, their absolute normalisation could potentially be quite sensitive 
to the priors on our time-independent parameters. To investigate this issue, we begin by 
comparing priors against posteriors for the nine time-independent parameters of our model 
in Figure S3. This comparison reveals four of these parameters (pasymp. [M], pasymp. [F], pfalse 
pos., and pself cure, n.) as tightly constrained by the available data, and the remaining five 
(patt.|symp., ptest|symp., ppos., pself cure, a., and prep.) as relatively unconstrained (i.e., prior 
dominated). Our priors on patt.|symp., pself cure, a., and prep.—of which only the latter is without 
support from literature review (cf. Table S1)—enforce tight constraints on these parameters 
whereas our priors on ptest|symp. and ppos. are comparatively broad.  
We conduct an in-depth prior sensitivity analysis by considering two alternative prior 
distributions for each of the five parameters, patt.|symp., ptest|symp., ppos., pself cure, a., and prep., 
separately (dotted red and blue lines in Figure S3) where the modes of these new priors 
have been shifted. Instead of having to run an additional 2 x 5 = 10 ABC analyses, we run 
only another single ABC analysis using the broad (relaxed) prior distributions as indicated by 
the dashed lines in Figure S3. Then, the posterior results for a particular prior configuration 
can be obtained by simply applying importance sampling re-weighting of the ABC results 
obtained with the relaxed prior distributions. The first point we note upon examination of the 
posteriors under our relaxed priors on patt.|symp., pself cure, a., and prep. is that for the prep. 
parameter is quite similar to that for our original prior, revealing that in fact this parameter is 
well constrained by the data in a sense harmonious with our expectations (Figure S3). This 
significant degree of constraint by the available data is again reflecting in the limited 
response of our prevalence estimates to reweighting of the prep. parameter by our shifted 
priors, despite prep. being degenerate with no other model parameter (cf. Figure 1). 
Conversely, although patt.|symp., and pself cure, a. are only weakly constrained by the available 
data, they are each to some extent degenerate with pasymp., M/F and pself cure, n., respectively, 
such that forcing each in turn towards higher and lower values using our shifted priors forces 
the corresponding degenerate parameter(s) in the opposite direction while our data-driven 
prevalence estimates remain unchanged (Figure S4). The only parameter to notably respond 
to our shifted priors was ppos., which is only weakly degenerate with pasymp., M/F and pfalse pos.; 
though the resulting shifts in the normalisations of our prevalence estimates are ultimately 
much smaller than the differences identified between our various age-sex cohorts. 
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Figure S1: Number of chlamydia notifications, and chlamydia tests rebated by Medicare, 
in Australia, 2001-2013 
 
 
Figure S2: Simple model deduced relationship between prevalence rates and testing 
rates for different levels (contours) of positivity 
 
Figure S3: Comparison of prior and posterior densities for the nine time independent 
parameters of our decision pathway diagram 
 
Figure S4: Prior-sensitivity in our prevalence estimates explored by importance sample 
reweighting under alternative, shifted priors 
 
Table S1: Key parameters for prior specification in our Bayesian model for chlamydia  
Time-independent Parameters 
Parameter* Description of 
parameter 
2.5% Q. Mode 97.5% Q. Beta 
params 
Reference(s) 
pasymp. [M] Proportion of 
asymptomatic 
infections (males) 
0.881 0.910 0.934 400 
40 
[1, 2] 
pasymp. [F] Proportion of 
asymptomatic 
infections (females) 
0.808 0.843 0.873 400 
75 
[3] 
patt.|symp. Proportion of 
symptomatic 
infections who seek 
medical care 
0.896 0.905 0.913 4000 
420 
[4, 5] 
ptest|symp. Proportion of 
symptomatic patients 
(who visit a clinic) 
tested 
0.901 0.957 0.987 83 
4 
Expert opinion  
ppos. True positive rate of 
diagnostic test  
0.891 0.943 0.975 110 
7 
[6, 7] 
pfalse pos. False positive rate of 
diagnostic test 
0.001 0.007 0.022 2 
250 
[6, 7] 
pself cure, a. Proportion of 
infections cleared by 
background antibiotic 
use 
0.090 0.095 0.101 1050 
10000 
[8] 
pself cure, n. Proportion of 
infections that clear 
naturally  
0.321 0.458 0.599 22 
26 
[9, 10] 
prep. Proportion of tests 
that are reported to 
NNDSS by labs 
0.990 0.995 0.998 1500 
8 
Expert opinion 
 
Time-dependent Parameters 
Parameter† Description of 
parameter 
Matérn Covariance Parameters (w/ Logistic Trans.) 
Expectation Variance Range Smoothness 
pinf., t  Probability of 
experiencing 
chlamydia infection 
in a given year  
-3.5 2 12 1.5 
ptest|asymp., t  Probability of 
attending 
asymptomatic testing 
in a given year 
-2.75 2 12 1.5 
† 
With the probabilities of infection and screening in each of six age-based cohorts for each sex given the 
freedom to vary each year in our model, we encode our a priori expectation of relatively gradual changes over 
time (with some correlation between similar age groups) via a multivariate Gaussian prior structure with Matérn 
covariance function. To ensure probabilities between zero and one we in fact apply this prior to logistic 
transformed versions of each parameter, y=log(p)/(1-log(p)). Specification of the Matérn covariance function is by 
way of its prior expectation, variance, range, and smoothness; our choice of a large prior variance for (the logistic 
transformed version of) each of these parameters gives a deliberately broad, non-informative range, allowing the 
dataset to “speak for itself” most clearly here (see Supplementary Material for more details). 
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